One third of patients treated with ipilimumab, an anti-CTLA-4 antibody, develop diarrhea and 16% of patients will go on to develop severe colitis, which can lead to perforations (0.5%) and/or colectomy [4, 11]. This evidence concerns the gene CTLA4 and colitis.